Xeris Biopharma Holdings, Inc. (XERS) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 9 Buy, 1 Hold.
The consensus price target is $13.50 (low: $9.00, high: $18.00), representing an upside of 122.4% from the current price $6.07.
Analysts estimate Earnings Per Share (EPS) of $-0.36 and revenue of $0.20B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.37 vs est $-0.36 (missed -3%). 2025: actual $0.00 vs est $-0.02 (beat +115.8%). Analyst accuracy: 0%.
XERS Stock — 12-Month Price Forecast
$13.50
▲ +122.41% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Xeris Biopharma Holdings, Inc., the average price target is $13.50, with a high forecast of $18.00, and a low forecast of $9.00.
The average price target represents a +122.41% change from the last price of $6.07.
Highest Price Target
$18.00
Average Price Target
$13.50
Lowest Price Target
$9.00
XERS Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Xeris Biopharma Holdings, Inc. in the past 3 months
EPS Estimates — XERS
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.37
vs Est –$0.36
▼ 2.9% off
2025
Actual $0.00
vs Est –$0.02
▲ 730.9% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — XERS
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.203B
vs Est $0.201B
▲ 1.0% off
2025
Actual $0.292B
vs Est $0.288B
▲ 1.2% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
